sensorion

Sensorion Appoints Former Ablynx CEO, Dr. Edwin Moses, as Chairman of the Board

MONTPELLIER, FRANCE —  Sensorion, a clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced the appointment of Edwin Moses, former Chief Executive Officer of Ablynx, as Chairman of its Board of Directors. 

Edwin brings more than 25 years of executive experience as both CEO and Chairman of numerous life science companies. He was Chairman and then CEO of Ablynx over 14 years, leading its rapid growth from a small research-focused organization to one of Europe’s most successful biotechnology companies, listed on Euronext Brussels and NASDAQ, until its €3.9 billion ($4.4 billion USD) acquisition by Sanofi in 2018.

Similarly, he led the growth, listing and eventual sale of pharmaceutical services company Oxford Asymmetry International as CEO and later as Chairman between 1993-2001. Edwin has raised more than €500 million ($565M USD) in equity and debt financing and has negotiated multiple major collaborations with leading pharmaceutical companies. He currently is Chairman of Achilles Therapeutics Ltd, Avantium NV and LabGenius Ltd, and is an Operating Partner at Keensight Capital. 

“Sensorion’s lead program SENS-401, in Phase 2 clinical testing, has promising potential to treat sudden sensorineural hearing loss, including that commonly experienced by soldiers after auditory trauma, as well as other forms of hearing loss. Additionally, the notable partnership with Institut Pasteur, to discover and develop a wide range of gene therapies for rare hearing disorders, may help many people who currently have no satisfactory therapeutic options. I am truly excited to be taking on the role of Chairman at such an important time in the development of Sensorion and look forward to joining the exceptional scientific and business team supporting the Company on this exciting journey”

–Dr Edwin Moses 

“It is an extraordinary opportunity for Sensorion to have Edwin Moses as a Board Member. All members of Sensorion’s Board agree that Edwin’s outstanding experience and successful record will be of great benefit to the Company,” commented Patrick Langlois, the outgoing Chairman of the Board. “On a personal basis, I was very much convinced that his expertise and potential contribution would also justify his appointment as Chairman of the Board, with immediate effect. I am confident, based on recent achievements, that Sensorion under the leadership of Edwin Moses and Nawal Ouzren will continue to emerge as a global leader in treating hearing loss.” 

“We are honored and delighted to welcome Edwin as Chairman of Sensorion. He brings invaluable experience in all elements of leadership in the biotech industry, from research and clinical development to financing, regulatory approval, partnering and M&A,” said Nawal Ouzren, CEO of Sensorion.

“His appointment further strengthens our leadership team and will add momentum to the development of our expanding hearing loss pipeline, including gene therapy for monogenic forms of hearing loss, as well as the clinical development of our lead product SENS-401 to treat sudden sensorineural hearing loss, for which we expect to report top-line Phase 2 clinical data in mid-2021. I would also like to extend my gratitude to Patrick Langlois for his dedicated service as Chairman of Sensorion over the last five years. Patrick’s knowledge and expertise have been important factors guiding the Company to this important transition. He leaves us in a strong position, and we wish him all the best for the future”. 

–Nawal Ouzren, CEO of Sensorion

 

About Sensorion

Sensorion is a pioneering clinical-stage biotechnology company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. In the second half of 2019, Sensorion launched two preclinical gene therapy programs aiming at correcting hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin. The Company is uniquely placed, through its platforms and pipeline of potential therapeutics, to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders, a significant global unmet medical need. 


Leave a Reply

Your email address will not be published.